7.06
0.43%
0.03
시간 외 거래:
6.99
-0.07
-0.99%
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Drop in Short Interest - MarketBeat
BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire
BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland | BCRX Stock News - StockTitan
(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Avian influenza Treatment Market Growth Trends: Regional - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com
HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat
Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com India
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com
BioCryst Awards Key Talent with $8.01 Stock Options, RSU Compensation Package | BCRX Stock News - StockTitan
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highli - GuruFocus.com
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth By Investing.com - Investing.com Australia
BioCryst: Q3 Earnings Snapshot - Darien Times
BioCryst shares hold Buy rating, BofA sees entry point By Investing.com - Investing.com Canada
Piper Sandler lifts BioCryst Pharma target to $21 on Q3 beat - Investing.com UK
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript - AOL
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
BioCryst Pharmaceuticals Q3 2024 Earnings: EPS Loss of $0.07, Re - GuruFocus.com
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
BioCryst Pharmaceuticals Q3 2024 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Rice Hall James & Associates LLC - MarketBeat
‘Breakthrough’ quarter for Island Pharmaceuticals - The Mercury
Island Pharmaceuticals enjoys big quarter - Courier Mail
Semanteon Capital Management LP Invests $1.14 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Monday - MarketBeat
When (BCRX) Moves Investors should Listen - Stock Traders Daily
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% - MSN
What's Going On With BioCryst Pharmaceuticals Stock? - MSN
BioCryst Presents New Real-World Evidence Showing High - GlobeNewswire
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 4.7%Here's What Happened - MarketBeat
자본화:
|
볼륨(24시간):